Join Growin Stock Community!

Transcode therapeutics, inc.RNAZ.US Overview

US StockHealthcare
(No presentation for RNAZ)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

RNAZ AI Insights

RNAZ Overall Performance

RNAZ AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

RNAZ Recent Performance

6.14%

Transcode therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

RNAZ PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

RNAZ Key Information

RNAZ Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

RNAZ Profile

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA–based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Price of RNAZ

RNAZ FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

RNAZ Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-29.59
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
6.30
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-29.59
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
6.30
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is RNAZ's latest earnings report released?

    The most recent financial report for Transcode therapeutics, inc. (RNAZ) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating RNAZ's short-term business performance and financial health. For the latest updates on RNAZ's earnings releases, visit this page regularly.

  • How much cash does RNAZ have?

    At the end of the period, Transcode therapeutics, inc. (RNAZ) held Total Cash and Cash Equivalents of 2.84M, accounting for 0.54 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is RNAZ's EPS continuing to grow?

    According to the past four quarterly reports, Transcode therapeutics, inc. (RNAZ)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -4.86M. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of RNAZ?

    Transcode therapeutics, inc. (RNAZ)'s Free Cash Flow (FCF) for the period is -4.08M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 4.02% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.